Cleerly

Cleerly is a digital healthcare company revolutionizing cardiovascular care through AI-powered analysis of coronary computed tomography angiography (CCTA). Their clinically-proven platform aims to transform how clinicians approach heart disease treatment by precisely identifying and defining atherosclerosis earlier in the disease process. Cleerly's technology measures atherosclerosis directly, rather than relying on indirect markers like risk factors or symptoms. This approach allows for more accurate heart disease evaluation and personalized treatment plans. The company's AI-enabled digital care pathway offers faster, more precise heart disease assessment, improving both clinical and financial outcomes. Cleerly's impact is significant, addressing the fact that over 50% of heart attack victims are considered low risk by traditional clinical scoring, and 75% of lesions responsible for heart attacks cause only mild artery narrowing, often missed by conventional stress testing. The company is currently conducting TRANSFORM, a large-scale clinical trial involving 7,500 patients across more than 100 sites over five years, aiming to further validate their approach and potentially change the paradigm of cardiovascular prevention. Cleerly's technology has been embraced by leading cardiologists and is seen as a potential game-changer in cardiac care, offering a more comprehensive and precise method for assessing coronary artery health.